A observational long term Phase I/II study of the MAG200 randomised, double blind, placebo-controlled, single ascending dose study to evaluate the efficacy and longer-term safety and tolerability of allogeneic adipose-derived mesenchymal stem cells in the treatment of symptomatic knee osteoarthritis.
Latest Information Update: 26 May 2021
At a glance
- Drugs MAG 200 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Magellan Biologicals
- 26 May 2021 New trial record